Skip to main content
TipRanks
Go Ultimate75% OFF

Propanc Biopharma (PPCB) Stock Price & Analysis

83 Followers

PPCB Stock Chart & Stats

$1.94$0.02(1.04%)
At close: 4:00 PM EST
$0$10$20Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
$1.91 - $1.98
52-Week Range
$1.63 - $315.17
Previous Close
$1.92
Volume
N/A
Average Volume (3M)
36.73K
Market Cap
$2.01M
Enterprise Value
$3.62M
Total Cash (Recent Filing)
$258.37K
Total Debt (Recent Filing)
$42.74K
Price to Earnings (P/E)
―
Beta
-0.86
Next Earnings
N/A
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Low Leverage

Very low reported debt reduces fixed financial obligations and limits leverage-related pressure on the business. Positive equity also provides a remaining capital base, giving the company more flexibility than a similarly unprofitable developer with a highly indebted balance sheet.

Losses Narrowing

The substantial reduction in losses from FY2025 indicates that the company has moved away from its earlier peak level of expense or impairment burden. Although profitability remains deeply negative, lower losses could improve capital efficiency if the trend persists alongside clinical development.

Focused Oncology Pipeline

A defined focus on oncology gives Propanc a concentrated strategic direction rather than a broad, unfocused development portfolio. Its therapeutic candidates provide a clear basis for future value creation if research and development translate into clinical and regulatory progress.

Bears Say

No Revenue And Large Losses

The absence of reported revenue means the company has not yet demonstrated commercial traction or an operating model that can support itself. Persistent large losses limit earnings visibility and leave future financial performance dependent on successful development and eventual commercialization.

Persistent Cash Burn

Ongoing negative operating and free cash flow shows that Propanc is consuming cash to fund operations rather than generating internal financing. Continued burn can erode its capital base and increase the importance of future financing or other funding sources for development.

Nasdaq Delisting Risk

The listing deficiency creates a structural financing and market-access risk beyond ordinary share-price volatility. A future delisting could reduce trading liquidity, constrain public-market capital raising, and limit equity-based incentives, complicating the company’s ability to fund development.

Propanc Biopharma News

PPCB FAQ

What was Propanc Biopharma’s price range in the past 12 months?
Propanc Biopharma lowest stock price was $1.63 and its highest was $315.17 in the past 12 months.
What is Propanc Biopharma’s market cap?
Propanc Biopharma’s market cap is $2.01M.
When is Propanc Biopharma’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Propanc Biopharma’s earnings last quarter?
Propanc Biopharma released its earnings results on Nov 23, 2026. The company reported -$12.217 earnings per share for the quarter.
Is Propanc Biopharma overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Propanc Biopharma pay dividends?
Propanc Biopharma does not currently pay dividends.
What is Propanc Biopharma’s EPS estimate?
Propanc Biopharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Propanc Biopharma have?
Propanc Biopharma has 1,033,112 shares outstanding.
What happened to Propanc Biopharma’s price movement after its last earnings report?
Propanc Biopharma reported an EPS of -$12.217 in its last earnings report. Following the earnings report the stock price went down -3.956%.
Which hedge fund is a major shareholder of Propanc Biopharma?
Currently, no hedge funds are holding shares in PPCB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology